Endo Int'l (ENDP) Tops Q2 EPS by 12c, Affirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Endo Reports Second Quarter 2016 Financial Results
August 8, 2016 4:29 PM EDTDUBLIN, Aug. 8, 2016 /PRNewswire/ --
Second quarter 2016 reported revenues of $921 million and diluted GAAP earnings per share (EPS) from continuing operations of $1.75 Second quarter 2016 adjusted diluted EPS of $0.86 Company affirms full year 2016 revenue and adjusted diluted EPS financial guidance Company expands management capabilities, appointing Joseph J. Ciaffoni to President, U.S. Branded PharmaceuticalsEndo International plc (NASDAQ: ENDP) (TSX: ENL) today reported second quarter 2016 financial results, including:
Revenues of $921... MoreEndo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals
August 8, 2016 4:06 PM EDTDUBLIN, Aug. 8, 2016 /PRNewswire/ --Â Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today the appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals, effective August 15, 2016. Â
"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets. His proven track record of success across nearly 20 product launches and the commercialization of more than 70... More
